Dr Mehra on the FDA Breakthrough Therapy Designation for Amivantamab in HNSCC

Ranee Mehra, MD, discusses the FDA breakthrough therapy designation for amivantamab and hyaluronidase for patients with recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the efficacy of subcutaneous amivantamab plus pembrolizumab in patients with first-line recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the toxicities associated with subcutaneous amivantamab in recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the design of the OrigAMI-5 trial of pembrolizumab plus amivantamab and carboplatin for recurrent or metastatic HNSCC.

Ranee Mehra, MD, highlights how the ongoing OrigAMI-5 study may address an unmet need for patients with treatment-naive, recurrent or metastatic HNSCC.